Cancer Genome Atlas of China:Lung Cancer
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
- Status
- UNKNOWN
- Phase
- N/A
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
- Status
- COMPLETED
- Phase
- PHASE2
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
- Status
- COMPLETED
- Phase
- PHASE3
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
- Status
- COMPLETED
- Phase
- N/A
Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
- Status
- WITHDRAWN
- Phase
- PHASE3
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3